SVV-001 is under clinical development by Seneca Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SVV-001’s likelihood of approval (LoA) and phase transition for Retinoblastoma took place on 30 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SVV-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SVV-001 overview

SVV-001 (Seneca Valley virus-001) is under development for treatment of adrenocortical carcinoma, neuroblastoma, retinoblastoma, rhabdomyosarcoma, Wilms' tumor (nephroblastoma) and carcinoid tumors. The drug candidate is administered intravenously and is developed based on ViruScreen technology (technology of oncolytic viruses). It acts by targeting cells expressing TEM8 (Tumor Endothelial Marker 8). It was under development for small-cell lung cancer, non small cell lung cancer and glioblastoma.

Seneca Therapeutics overview

Seneca Therapeutics., is a developer of cancer therapeutics and vaccines for infectious disease. The company is headquartered in United States.

Quick View SVV-001 LOA Data

Report Segments
  • Innovator
Drug Name
  • SVV-001
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Seneca Therapeutics
  • Originator: Novartis
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.